People with dark-pigmented skin who have lupus are more prone to experience discoid lupus erythematosus, a form of chronic ...

Although the symptoms of discoid lupus usually only impact the skin, in rare circumstances, the disease can progress to ...

The lesions now referred to as discoid lupus were described in 1833 by Cazenave ... The first published illustrations of lupus erythematosus were included in von Hebra's text, Atlas of Skin Diseases, ...

LR is a rash that results from dilation of capillary blood vessels and stagnation of blood within these vessels causes mottled discoloration of the skin. It is described as being reticular (net ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Patient Chart Dynamix™ is an independent, data-driven service that unveils real-world patient management trends via large-scale patient chart audits. Designed to quantify practice patterns, measure ...

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

1 Since both the rejection of a skin homograft and the manifestations of disseminated lupus erythematosus may be mediated through "antitissue antibodies" this work was extended to patients with ...

Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s pathophysiology. Deucravacitinib yielded improvements in disease severity by week 16.

In a small phase II trial of cutaneous lupus erythematosus ... CLE may occur in association with systemic lupus erythematosus (SLE). The most common subtypes are discoid (DLE) and subacute ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...